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S364 Poster Session IIapproaches. Two individual case presentations will be presented of
patients treated at our institution who developed resistant herpes
simplex infections. The clinical course and treatment history will
be provided. These cases also necessitated a multidisciplinary ap-
proach that included wound care, pain service and infectious disease.
In the both cases, the patients were initiated on topical Cidofovir, an
institutional compounded formulation. One patient was prescribed
a topical cream application and the other a topical oral solution. It
was observed that acute renal failure developed within a short time
frame after initiation of the topical Cidofovir in both cases. The
treatment of herpes simplex infections in the immuncompromised
patient can be challenging for the clinical provider especially when
resistance has developed. Additionally, it is debilitating and painful
to the patient. The efficacy and safety of topical Cidofovir warrants
further careful investigation as demonstrated by the clinical course of
these two cases.589
COMPLEX DISCHARGE COORDINATION: IMPROVING HOSPITAL FLOW,
FAMILY SATISFACTION AND SAFETY
Baker, A.L., Berger, S.J., Bessler, L., Rigby, S., Spear, S., Gold, J.,
Friend, L., Lake, M., Boughner, A., Borich, A.M., Flesch, L.,
Freeman, B., Lawrence, J., Maas, D., Turner, K., Liming, B. Cincinnati
Children’s Hospital Medical Center, Cincinnati, OH
Purpose:Development of a highly-reliable, efficient discharge pro-
cess between the inpatient Blood and Marrow Transplant (BMT)
program and Home Health Care at Cincinnati Children’s Hospital
Medical Center.
Aim: That 80% of all patients discharged from the inpatient unit
meet the goal of being discharged on or before 1600.
Background:The BMTunit averages 25 discharges per month with
themajority utilizing theHomeCare department.We identified that
the day of discharge for new BMT patients was often chaotic with
accruing issues that resulted in delayed discharges.
Method and Design: Beginning in July 2009, discussions began
among key members of the team to improve the discharge process
for families. Data was collected and evaluated on a monthly basis.
Reasons for late discharges were evaluated, utilizing a Pareto Chart,
which demonstrated multiple offending factors. A series of small
tests of change were performed monthly with multiple revisions
using PDSA (Plan/Do/Study/Act) cycles.
Findings: Factors impacting discharge included the need for con-
tinuing education, scheduled treatments on day of discharge, trans-
portation issues, incomplete comprehensive discharge summary, and
timeliness in filling outpatient oral prescriptions. PDSA cycles im-
plemented included the ‘‘Pathway to Discharge’’ educational tool
for families, ‘‘Interdisciplinary Pathway to Discharge’’ tool for staff,
discharge family conferences and use of an online prediction tool.
Beginning in July 2009, 71% of patients were being discharged by
1600. The latest evaluated data shows that 91% of patients are being
discharged by the goal of 1600.590
TRIAGE AT THE SCCA TRANSPLANT CLINIC
Stener, C.L. Seattle Cancer Care Alliance, Seattle, WA
Purpose: Triage is the process of assessing patient’s clinical com-
plaints and symptoms and then setting a priority for treatment based
on the acuity of their condition. In the BMT population, it is essen-
tial to provide 24/7 accessibility of nursing staff on the telephone and
in person for patients to ask questions, be assessed and to provide
treatment if necessary.
Background: Our clinic is located in a large urban area which is af-
filiated with an academic teaching hospital and a pediatric hospital.
We perform greater than 520 transplants a year which consist of au-
tologous, synergenic, and allogenic (related, unrelated and cord
blood) transplants. Daily there is an average acute census of 160
outpatients.
Intervention: Inmost cases patients can remain on an outpatient ba-
sis during transplant conditioning. We infuse stem cell products in
the OPD except bone marrow and cord blood. Patients are admitted
based on clinical need, and then discharged on very liberal clinicalcriteria. When hospitalized the length of stay averages 1-3 weeks.
By doing this there’s a higher level of acuity with outpatients who
need immediate access to care at all times. To accommodate these
patients we have developed a robust triage process. There is 24/7 ac-
cess for care, when the OPD closes patients or the caregiver can call
the inpatient facility where a nurse is designated to field these calls
which will provide the needed support or intervention. If seen in
the late evening or early morning the assigned nurse will fax a report
to the OPD to explain why the patient was seen, if follow up is
needed or if the patient was admitted.
Evaluation: Triage has enhanced our ability to provide immediate
patient support and intervention. As a result of this triage process
the length of stay in the hospital has been shortened. Additionally,
this process has increased the confidence and competence of patients
and care givers for outpatient care management following a BMT.591
IMPROVING INSTITUTIONAL TIMELINE FROM FORMAL DONOR SEARCH
TO TRANSPLANTATION
Risley, G.L.10124, Krugh, D.M.10124 1OSUMC - James Cancer Hospital,
Columbus, OH
Purpose/Background: The National Marrow Donor Program
(NMDP) 2007 Transplant Center Performance report showed that
the turnaround time for our Center ranged from 58 to 3303 days
from formal search to transplantation. We had no data available to
determine the cause of the variability and the large expanse from for-
mal search to transplant. It was determined that strategies needed to
be developed to identify and improve the factors that influenced our
timeline.
Approach/Method: A performance improvement project to track
data on all formal searches was initiated. This data included the
date the formal search was initiated, the date of donor identification,
and the date of transplantation. The data was also linked to the dis-
ease being treated and individual physicians to identify any opportu-
nities for improvement. The Medical Director initiated an
intervention with any outlier physicians who had ongoing searches.
In addition, beginning in 2009 the reason the patient did not proceed
to transplant was tracked. Patients in a remission who had an identi-
fied donor were reviewed to see if they were proceeding to trans-
plant. Those not proceeding until a relapse occurred had their
searches closed. Finally, the Coordinators were reassigned so that
only one Coordinator was responsible for all activities related to
NMDP searches. This streamlined the communication with the
NMDP and the physicians.
Results: After tracking the data for one year we have shown modest
improvement. The March, 2010 NMDP Transplant Center Perfor-
mance report demonstrated that our days from formal search to
transplant had decreased to 33-749 days. From 2007-2009 the num-
ber of days from formal search to donor identification remained sta-
ble. The number of patients having a donor identified who then
proceeded to transplant has increased from 36% to 62%. Mean
days from initiation of donor search to transplant has decreased by
36% and from donor identification to transplant has decreased by
66%.
Conclusions: Utilization of a donor tracking spread sheet has
helped to identify a patient population whose timing of formal search
needs reviewed before implementing. We will continue to maintain
one Search Coordinator as communication with the NMDP and
physicians is a key factor. There is a plan to continue tracking to en-
sure that improvement is maintained and to try and identify other
areas that could be improved upon.592
SYMPTOM ASSESSMENT AND OPTIMAL MANAGEMENT OF OCULAR
GRAFT VERSUS HOST DISEASE
Heffernan, M.J. Fred Hutchinson Cancer Research Center, Seattle, WA
Ocular graft versus host disease is a common complication follow-
ing allogeneic hematopoietic stem cell transplantation affecting
more than 40-60% of patients with chronic graft versus host disease.
Common ocular structures affected include the eyelid, lacrimal
gland, conjunctiva and cornea. Infiltration of the lacrimal glands
Poster Session II S365and conjunctiva with T-cells leading to inflammatory-mediated dys-
function of the secretory epithelium is thought to contribute to its
development.
Ocular symptomsmay be the presenting feature ofGVHD, occur-
ring in the absence of other systemic manifestations of GVHD. The
initial subclinical symptoms commonly reported by patients include
excessive tearing, nonspecific discomfort or sense of foreign object,
and mild photophobia.
Keratoconjunctivitis sicca (KCS) characterized as dryness of the
conjunctiva and cornea is the most common clinical manifestation
of ocular GVHD. KCS may lead to corneal erosions and filaments
causing significant pain and photophobia. Severe KCS with corneal
ulceration may lead to loss of vision. Once lacrimal gland scarring
occurs, the damage caused by ocular GVHD is irreversible and can
profoundly impact the patient’s quality of life.
Recognition of the early signs and symptoms of ocular GVHD
leads to appropriate diagnostic testing, timely treatment and reduc-
tion in morbidity.
The purpose of this presentation is to provide a clinical overview
of ocular GVHD to hematopoietic stem cell transplant nurses, high-
lighting their role in identifying the often subtle signs and symptoms
of its initial presentation. Also included, will be an overview of the
diagnostic evaluation, treatment options and common nursing inter-
ventions specific to the nursing management and educational needs
of these patients.593
STEM CELL COLLECTION: A TALE OF TWO UNITS. A UK/US COMPARISON
Baker, J. Royal Marsden Hospital, Sutton, Surrey, United Kingdom
Working in a JACIE accredited transplant center, we apheresis
nurses strive to achieve and manage a nurse-led,evidence based,col-
laborative service providing exemplary patient and donor care in the
collection of peripheral hematopoietic stem cells for autologous and
sibling transplant.
There is perhaps a general assumption that in this specialist area
there are more similarities than differences with regards to practice
both nationally and internationally.
This presentation is an overview of two apheresis units looking at
some core elements of patient management.One is my own unit at
the Royal Marsden Hospital, a JACIE accredited, respected cancer
hospital in the UK. The other is a consistently highly ranked
FACT accredited academic medical center,the Cleveland Clinic in
Ohio,US.
The following discussion highlights some significant differences
and proves that across the pond we are divided by more than just
a common language!
It will be interesting to ascertain if colleagues in the audience rec-
ognise and identify with current practice at my institution or that of
the US.
Noteworthy areas for comparison are nurse education and train-
ing; nurse-led vs. medical led service;peripheral vs. central intrave-
nous access; management of citrate toxicity; donor care; apheresis
procedures, and CD34 target yields.
There may be a more medicalised approach to stem cell collection
in this particular US unit with perhaps increased economic and
healthcare implications.594
NEW HOPE: SUPPORTIVE NURSING CARE FOR MULTIPLE SCLEROSIS
PATIENTS RECEIVING AN AUTOLOGOUS TRANSPLANT
Rochester, J.M. Seattle Cancer Care Alliance, Seattle, WA
MS is an immune mediated disease of the central nervous system
causing nerve demyelination and progressive degeneration.
Common symptoms include: muscle strength changes, visual com-
plications and sensory alterations. Bladder, bowel and sexual dys-
function are common, along with speech and swallowing
symptoms, heat sensitivity, cognitive impairment and fatigue.
Purpose:The FredHutchinson Cancer Research Center (FHCRC)
is participating in an NCI phase II multi-center trial offering high-
dose immunosuppressive therapy involving rescue with autologousCD 34+ selected hematopoietic stem cells for MS patients. We are
utilizing therapy used in treating malignancy to also treat an autoim-
mune disease. It is hypothesized that this intensive therapy will arrest
disease activity in these individuals. The nursing care for these pa-
tients is crucial for a successful outcome.
Interventions:This study opened in 2006 and 24 patients have been
transplanted with five year followup. Multiple Sclerosis is a complex
disease associated with various physical, emotional and cognitive im-
pairments. Fatigue is an on-going problem and heat exacerbates
symptoms. Bladder dysfunction may require intervention to control
urinary urgency and increased risk of urinary tract infections.
Evaluation: Caring for MS patients contrasted with cancer patients
can be challenging for the transplant nurse. Teaching and nursing
care must be designed for the special needs of these patients. Toxic-
ities of chemotherapy and immunosuppression present new chal-
lenges for the patient. Fevers can lead to significant dysfunction.
Education about fall risks is important for safety. Giving patients
instructions in writing can be helpful because of possible cognitive
impairment.
Discussion: Nurses are challenged to go beyond traditional trans-
plant expertise for education of family members andMS patients go-
ing through a transplant. Toxicities from transplant include: MS
flares with fever and GCSF use during mobilization, increased sus-
ceptibility for EBV post transplant lymphoproliferative disorder,
engraftment syndrome andCMV.Nurses are now in a position to in-
tegrate the concept of hope into the clinical management of a disease
that was thought to be hopeless.595
CHALLENGES IN DIAGNOSIS AND TREATMENT OF HHV6 DURING
ALLOGENIC STEM CELL TRANSPLANTATION
Zanter, A.K. Duke University Hospital, Durham, NC
Human herpesvirus 6 (HHV-6) is a common virus that when reac-
tivated in patients undergoing allogenic stem cell transplant can cre-
ate many challenges in their care and treatment. Most commonly,
HHV-6 is known to cause suppression of hematopoiesis resulting
in graft rejection and graft failure. Reactivation has been noted to oc-
cur between 2-4 weeks after transplant. The incidence of HHV-6 in-
fection is known to be higher in patients undergoing allogenic
transplant, specifically among patients with unrelated or mis-
matched donors due to the increased level of immunosuppression
during and after their conditioning regimens to prevent graft versus
host disease.
Among our allogenic transplants from January 2009 until the pres-
ent, approximately 27 patients have developed HHV6 viremia. This
has been challenging as there are no clear guidelines for monitoring
levels and treatment initiation guidelines. This year our program
routinely sentHHV-6 PCRblood samples weekly during the perien-
graftment period on all patients who received cord blood and non-
myeloablative allografts.We consider initiating treatmentwhen viral
loads are .200 copies.
The treatment of HHV-6 relies on the use of one of two anti-viral
medications, foscarnet and ganciclovir. Our program uses an induc-
tion regimen of twice daily treatment for two weeks followed by
a maintenance regimen of once daily for two weeks. The viral
PCR is monitored weekly and treatment is discontinued after 4
weeks of therapy if the virus in no longer detected.Weekly monitor-
ing must be continued among these patients to monitor for re-acti-
vation. Our experience highlights the need for further research into
the treatment of HHV-6.596
TRANSFORMING CARE AT THE BEDSIDE WITH AN EVIDENCED BASED
SKILLS DAY APPROACH
Munaretto, M., Anderson, L., Komoto, B., Hattori, Y. City of Hope,
Duarte, CA
Background and Significance: Transforming care at the bedside
was the focus of a 2003 Robert Wood Johnson Foundation grant.
A successful pilot at the University of Pittsburgh Medical Center,
Shadyside, demonstrated improved patient care utilizing work re-de-
sign by front line staff to: 1) center improvement around staff or
